Arbutus Biopharma (ABUS) Depreciation & Amortization (CF) (2018 - 2026)
Arbutus Biopharma (ABUS) posted Depreciation & Amortization (CF) of $11000.0 for Q1 2026, little changed sequentially from $11000.0 in Q3 2025, and down 96.67% YoY from $330000.0 in Q1 2025.
Powered by 
Analysis
Arbutus Biopharma (ABUS) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Arbutus Biopharma has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $11000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 96.67% year-over-year to $11000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33000.0 (down 96.77% YoY) and the FY2025 annual result came in at $400000.0, down 71.43% from the prior year.
- Depreciation & Amortization (CF) steadied at $11000.0 in Q1 2026 per ABUS's latest filing, from $11000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $394000.0 in Q1 2022 and troughed at $11000.0 in Q2 2025.
- A 5-year average of $275000.0 and a median of $342000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) gained 7.58% in 2023, then plunged 96.91% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $343000.0 in 2022, then grew by 7.58% to $369000.0 in 2023, then dropped by 8.94% to $336000.0 in 2024, then plunged by 96.73% to $11000.0 in 2025, then changed by 0.0% to $11000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $11000.0, $11000.0, and $11000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Arbutus Biopharma | 1.02 Bn | 927.31 Mn | - | 11,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11,000.00 |
| Mar 31, 2026 | 11,000.00 |
| Sep 30, 2025 | 11,000.00 |
| Jun 30, 2025 | 11,000.00 |
| Mar 31, 2025 | 330,000.00 |
| Sep 30, 2024 | 336,000.00 |
| Jun 30, 2024 | 356,000.00 |
| Mar 31, 2024 | 355,000.00 |
| Sep 30, 2023 | 369,000.00 |
| Jun 30, 2023 | 342,000.00 |
| Mar 31, 2023 | 334,000.00 |
| Sep 30, 2022 | 343,000.00 |
| Jun 30, 2022 | 383,000.00 |
| Mar 31, 2022 | 394,000.00 |
| Sep 30, 2021 | 447,000.00 |
| Jun 30, 2021 | 436,000.00 |
| Mar 31, 2021 | 443,000.00 |
| Sep 30, 2020 | 490,000.00 |
| Jun 30, 2020 | 501,000.00 |
| Mar 31, 2020 | 500,000.00 |